Drugs / PD 0360324
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01470313 | Nov 2011 → Nov 2013 | cutaneous lupus erythematosus | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00550355 | Aug 2007 → Jun 2009 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02554812 | Nov 2015 → Mar 2023 | cancer of unknown primary site | Pfizer | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02948101 | Dec 2018 → Feb 2019 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT01732211 | Mar → Sep 2013 | pulmonary sarcoidosis | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD 0360324 | “anti-CSF1 monoclonal antibody PD 0360324 (PD 0360324)” NCT02948101 ↗ |
| Action | Inhibit | “Anti-M-CSF” NCT02554812 ↗ |
| Modality | Monoclonal antibody | “a fully human immunoglobulin G2 monoclonal antibody against macrophage colony-stimulating factor” PMID 26376111 ↗ Nov 2015 |
| Route | Intravenous | “multiple intravenously administered doses of PD 0360324” NCT00550355 ↗ |
| Target | CSF1 | “anti-CSF1 monoclonal antibody PD 0360324” NCT02948101 ↗ |